Insider Cluster (2 insiders) ·Filed Aug 31, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed1mo ago
Insider cluster: 2 insiders, $560K total
Actionable Insight • Neutral

The selling is notable in size but comes from venture capital funds rather than management, reducing its predictive value. Monitor for further 10% owner sales or any change in the selling pace; if C-suite executives begin selling, the signal would strengthen. No immediate catalyst is apparent.

DirectionNeutral
Confidencemedium
Horizonweeks
Latest settled — T+20d ⚠ clustered
TRDA ▼ -10.18% at T+20d
NEUTRAL call ✗ call lost -10.18% · α vs SPY -10.50% · entry $7.07 → $6.35
Next anchor: T+60d in 8w
Entry anchored
Aug 31, 04:14 PM ET
via 1-min bar
T+1d
+3.25%
call +3.25% · α +2.81%
$7.30
settled 4w ago
T+5d
+0.57%
call +0.57% · α +0.48%
$7.11
settled 24d ago
T+20d
-10.18%
call -10.18% · α -10.50%
$6.35
settled 3d ago
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined ~$1.44M of TRDA shares over five days, representing ~0.53% of market cap. The selling is part of a broader pattern of insider sales ($1.8M in prior 30 days), but the sellers are venture capital funds rather than C-suite executives, weakening the bearish signal per academic literature on insider sales.

Key Financial Metrics

Direction
selling
Total Value
$1.4M
Insiders
2

Key Facts

  • MPM BioVentures 2014 and 2018 sold 8 blocks totaling ~$1.44M between Aug 26-31, 2026
  • Sales represent ~0.53% of TRDA's $273M market cap
  • Sellers are 10% owners (venture capital), not C-suite officers
  • Prior 30 days saw 10 insider sells totaling $1.8M, indicating a sustained distribution pattern

Financial Impact

~$1.44M in open-market sales by two related 10% owner entities over 5 days

insider ownershipfloat

Risk Factors

  • Continued distribution by large holders could pressure the stock
  • No near-term positive catalyst to offset selling overhang
  • Historical insider selling patterns on TRDA have not been strongly predictive of near-term price moves

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TRDA-1788246125176
18 reports for TRDA
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +58.52%May 4, 2026
Filters
Rows
Reports for TRDA — sortable, filterable
TypeNow
Sep 9, 2026
22d ago
Insider Cluster
BEARISH ★ 6/10
$6.42 $6.90▼ −7.48%▼ −7.98%$5.38 (+16.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.17 $6.80▼ −5.16%▼ −4.01%$5.38 (−24.97%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.27 $7.17▼ −1.38%▼ −1.64%$5.38 (−26.00%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.04 $7.27▲ +3.27%▲ +3.67%$5.38 (−23.58%)
Aug 5, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$7.06 $7.67▲ +8.64%▲ +8.29%$5.38 (−23.80%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.24 $7.04▼ −2.76%▼ −2.66%$5.38 (−25.69%)
Jul 30, 2026
9w ago
144
BEARISH ★ 5/10
$6.79 $6.87▼ −1.18%▲ +2.33%$5.38 (+20.77%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 1, 2026